Vericel Corporation $VCEL Shares Sold by Kopp Family Office LLC

Key Points

• Kopp Family Office reduced its Vericel stake by 68.7% in the second quarter, selling 112,302 shares and retaining 51,053 shares valued at approximately $2.27 million.
• Vericel insiders sold 52,232 shares worth $2.3 million over the past 90 days, while the company’s latest quarter exceeded expectations with $0.04 EPS and $77.46 million in revenue, up 22.5% year over year.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $58.40 versus the stock’s reported $43.95 opening price.

Kopp Family Office LLC cut its position in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 68.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,053 shares of the biotechnology company's stock after selling 112,302 shares during the period. Vericel makes up 1.4% of Kopp Family Office LLC's holdings, making the stock its 13th biggest holding. Kopp Family Office LLC owned 0.10% of Vericel worth $2,271,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new stake in shares of Vericel in the 4th quarter valued at approximately $27,000. Quarry LP acquired a new position in Vericel in the fourth quarter valued at approximately $31,000. Farther Finance Advisors LLC lifted its holdings in Vericel by 116.5% in the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 522 shares during the last quarter. Truvestments Capital LLC grew its position in Vericel by 175.4% in the fourth quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 977 shares during the period. Finally, Empowered Funds LLC purchased a new position in Vericel in the fourth quarter worth approximately $58,000.

Insider Buying and Selling at Vericel

In related news, insider Jonathan Mark Hopper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00. Following the sale, the insider directly owned 75,753 shares of the company's stock, valued at $3,408,885. This represents a 11.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Siegal sold 4,500 shares of the firm's stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total transaction of $220,050.00. Following the completion of the transaction, the insider directly owned 1,078 shares of the company's stock, valued at $52,714.20. This represents a 80.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 52,232 shares of company stock worth $2,304,217. 7.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

VCEL has been the topic of a number of research analyst reports. Truist Financial restated a "buy" rating and issued a $58.00 target price (up from $54.00) on shares of Vericel in a research report on Friday, July 31st. Canaccord Genuity Group set a $60.00 price target on Vericel in a report on Thursday, July 30th. TD Cowen raised their price objective on Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Vericel in a report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of Vericel from a "sell (d+)" rating to a "hold (c)" rating in a research report on Friday, July 31st. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, Vericel has a consensus rating of "Moderate Buy" and an average target price of $58.40.

Vericel Price Performance

Shares of Vericel stock opened at $43.95 on Tuesday. The business has a 50-day moving average of $43.30 and a 200 day moving average of $37.73. Vericel Corporation has a 12 month low of $28.95 and a 12 month high of $49.32. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 93.51 and a beta of 1.06.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The company had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.01) earnings per share. Equities research analysts anticipate that Vericel Corporation will post 0.54 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source